Table 4.
Relative drug amounts [% of total UV areas] in human lung tissue slices
| Incubation time [h] | Parent compound | Active compound | Fatty acid esters | Inactive metabolite | |
| Beclomethasone | 2 | 21.4 ± 9.8 | 72.1 ± 9.2 | 2.9 ± 1.1 | 3.6 ± 0.8 |
| dipropionate2 | 6 | 9.2 ± 7.9 | 66.6 ± 17.7 | 4.4 ± 2.6 | 19.8 ± 10.0 |
| 24 | - | 26.6 ± 16.8 | 8.5 ± 7.8 | 64.9 ± 14.4 | |
| Budesonide1 | 2 | 72.2 ± 10.8 | 27.8 ± 10.8 | - | |
| 6 | 64.9 ± 12.0 | 35.1 ± 12.0 | - | ||
| 24 | 53.6 ± 11.5 | 46.4 ± 11.5 | - | ||
| Ciclesonide | 2 | 85.0 ± 3.4 | 9.9 ± 1.4 | 5.1 ± 2.1 | - |
| 6 | 73.5 ± 4.7 | 17.9 ± 1.5 | 8.6 ± 4.1 | - | |
| 24 | 40.0 ± 7.6 | 31.5 ± 2.4 | 28.5 ± 8.8 | - | |
| Fluticasone1 | 2 | 100 ± 0.0 | - | - | |
| propionate | 6 | 100 ± 0.0 | - | - | |
| 24 | 100 ± 0.0 | - | - | ||
Data are presented as mean ± standard deviation (n = 9).
1Parent and active compound.
2The active compound of BDP may be overestimated as inactive 21-BMP may be included.